FDA grants Fast Track designation to MS drug
FDA grants Fast Track designation to MS drug
MediciNova, Inc says it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of MN-166 (ibudilast) for the treatment of patients with progressive multiple sclerosis (progressive MS)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/